ABOUT US
THE TEST
With over twenty years of clinical testing, the product has an established track record for safety and accuracy. It has also undergone multiple clinical trials in Hong Kong and North America to confirm a high level of sensitivity and specificity for NPC detection.
Following a review by the US Food and Drug Administration, NP Screen is the first and currently only approved Class II medical device for the detection of nasopharyngeal cancer.
THE COMPANY
Some of the innovative devices under development by ASC include:
- Non-invasive, office or home-based devices for the screening of Human Papilloma virus-related oropharyngeal and anorectal cancers
- Home-testing devices for nasopharyngeal and cervical cancers
THE TEAM
Dr. John Phillips
BSc, M.A., M.D., F.R.C.S.C.
Associate Professor, Department of Surgery, University of Toronto
Dr. Phillips has been actively involved in the teaching and development of cranio-maxillofacial courses, as well as design and development of surgical tools on a national and international level.
He is an Associate Professor of Surgery at The University of Toronto and has extensive publications (75 papers at international meetings, 34 peer-reviewed articles, and 17 book chapters). He is experienced in handling regulatory issues pertaining to the launch of medical devices in North America.
Dr. Phillips is the chief liaison between the medical and scientific community, and oversees all regulatory issues related to NP Screen. He is also actively involved in product design and development, to ensure the best possible end-user experience.
Dr. Raymond Ng
M.D., Ph.D., F.R.C.S.C.
Assistant Professor, Department of Otolaryngology – Head and Neck Surgery, University of Toronto
Dr. Ng has extensive experience in clinical and laboratory data collection and analyses. He was involved in the original EBV DNA research with a team of researchers from Mount Sinai Hospital and Hospital for Sick Children and has co-authored publications on this subject.
As a surgeon, Dr. Ng has performed over 90,000 cases of endoscopy, and treated and managed hundreds of cases of NPC. He developed the concept of trans-oral access to the nasopharynx. He also designed, planned, and conducted the clinical trial during the development phase of NP Screen and was the project lead for the FDA clinical study.
Dr. Ng has treated well over 100,000 Chinese patients in Toronto from high-risk endemic areas for various ENT-related illnesses. He is an avid proponent for early detection of NPC and strives to make it accessible to patients worldwide.
Dr Erik Avaniss-Aghajani
Dr. Avaniss-Aghajani established the Q-PCR laboratory protocol and completed the validation study for NP Screen. In addition to being the Chief Scientific Advisor, he is also instrumental in setting up regional PCR laboratories around the globe to facilitate access to the NP Screen network.
Dr. Patrick J. Gullane
C.M., M.B., F.R.C.S.C., F.R.A.C.S., HON-F.R.A.C.S., HON-F.R.C.S.
Wharton Chair, Head and Neck Surgery, Princess Margaret Cancer Centre
Senior Scientist, Cancer Informatics, Ontario Cancer Institute
Professor, Department of Surgery, University of Toronto
Chair, Advancement Committee, Department of Otolaryngology, Head and Neck Surgery, University of Toronto
He was certified by the American Board of Otolaryngology – Head and Neck Surgery, and pursued advanced training in Head and Neck Oncology with Dr. Sebastian Arena in Pittsburgh, Drs. John Conley and Marquis Converse in New York.
He was recruited to the Department of Otolaryngology – Head and Neck Surgery at the University of Toronto, and holds numerous academic positions.
Dr. Gullane is known internationally for his innovation in the management of patients with head and neck cancers. He has published over 250 peer-reviewed papers and nine books on the subject.
The international recognition of his expertise was demonstrated by his selection as a faculty member in the 1st Educational World Tour of the International Federation of Head and Neck Oncologic Societies.
In 2010, Dr. Gullane was appointed as a member to the Order of Canada.
Professor William Wei
M.S., F.R.C.S.E., F.R.A.C.S. (Hon.), F.A.C.S., F.H.K.A.M. (ORL) (Surg)
Head, Department of Surgery, Director of Li Shu Pui ENT Head and Neck Surgery Centre, Hong Kong Sanatorium & Hospital
Professor Wei’s distinguished achievements include:
- Fellow of the Royal College of Surgeons of England
- Honorary Fellowship of the Royal Australasian College of Surgeons
- Honorary Fellowship of the Hong Kong College of Otorhinolaryngologists
- Honorary Fellowship of the German Society of Otolaryngology and Head and Neck Surgery
- Honorary Fellowship of the American College of Surgeons
Professor Wei was active in clinical research pursuits, holds memberships in 26 academic boards, and serves on the editorial boards of 41 international academic journals.
He is the founding President of the Hong Kong College of Otorhinolaryngologists and was President of the Hong Kong Head and Neck Society for two terms. He has also served as Director of the International Federation of Head and Neck Oncology Societies.
Currently, Professor Wei is Assistant Medical Superintendent, Head of Department of Surgery, and Director of Li Shu Pui ENT Head & Neck Surgery Centre at the Hong Kong Sanatorium and Hospital.
Mr. Leo Chui
Multiple launches in the military, medical, industrial, and commercial sectors
Operation Logistics & Processes,
Domestic and international ventures
Leo earned his Mechanical Engineering Degree from the University of British Columbia with a focus in Industrial Engineering. He also obtained his certification as IPC EMS Program Management. He has led the facility through ISO13485 and ITAR registration and successfully launched several multi-million-dollar projects in diverse sectors, including military, medical, industrial, and commercial.
Leo has been instrumental in customer and supplier contract negotiations, projects implementation, as well as operations management.
He is the chief operating officer for NP Screen and oversees the initiation of operation logistics and processes.